Status:

COMPLETED

IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Lead Sponsor:

Livzon Pharmaceutical Group Inc.

Conditions:

Peptic Ulcer Hemorrhage

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to compare the efficacy and safety of ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding. Patients with endoscopically diagnosed peptic ulc...

Detailed Description

Patients with endoscopically diagnosed gastric and duodenal ulcer bleeding were randomly assigned into two groups, ilaprazole and omeprazole. 120 patients were administrated 10 mg ilaprazole daily (at...

Eligibility Criteria

Inclusion

  • were 18-65 years of age, male or female.
  • had symptoms of hematemesis, hematochezia, melena within 24 hours and clinically diagnosed as peptic ulcer bleeding.
  • had endoscopically diagnosed gastric or duodenal ulcer bleeding (multiple ulcers was judged by the higher Forrest level).
  • were patients of Forrest Ⅰa-Ⅱb level and had successful endoscopic surgery to stop bleeding (bleeding was cured and the blood vessels were flat or became into the lumen). Ⅱc-Ⅲ grade patients did not receive endoscopic hemostasis.
  • voluntarily sign informed consent.

Exclusion

  • had hemorrhagic shock (systolic blood pressure\<90mmHg) or require surgery.
  • were non-ulcer bleeding and gastric ulcer biopsy proved malignant.
  • had gastrectomy and gastrointestinal anastomosis.
  • were suffering from serious heart, liver, brain, lung, kidney and other serious diseases.
  • had coagulation disorders (laboratory tests showed that platelets \<80 × 109 / L, PT abnormal and exceed the normal control for 3 seconds, APTT than the normal control for 10 seconds).
  • had hypersensitivity or idiosyncratic reaction to ilaprazole, omeprazole, esomeprazole or any other benzimidazole.
  • had positive result of urine pregnancy test.
  • used the same kind of drugs within 48 hours before entering the group.
  • need to continue the combination of the following drugs that have an effect on treatment during the study: NSAIDs, corticosteroids, heparin, warfarin and vitamin K, platelet antagonists or other hemostatic agents.
  • participated in a clinical trial with an investigational drug or device within the past three months.
  • had alcoholic intemperance, drug addiction or other factors that researchers think it unfit for drug clinical trials.

Key Trial Info

Start Date :

February 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT03362268

Start Date

February 1 2014

End Date

July 1 2014

Last Update

December 6 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.